巨头赛诺菲:Dupilumab业绩高涨94%;过专利药物迎来黄昏
2023-08-05 22:00
举报
Dupixent(IL-4R a)业绩为16.34亿欧元,同比大增93.8%;Praluent(PCSK9)业绩仅为1.46亿欧元,同比增长18%;波立维Plavix业绩为5....
相关阅读
2022-07-15
2021-09-07
2023-06-12
2023-02-20
2021-09-14
2021-11-07
2023-02-09
2021-11-24
2021-12-15
2021-09-16
2021-11-18
2021-12-04
